For patients undergoing radiation therapy for head and neck cancer, the treatment often brings a debilitating side effect: oral mucositis. This painful inflammation and ulceration of the mucous membranes can make swallowing impossible, leading to malnutrition and treatment interruptions. While clinicians have long used photobiomodulation (PBM) therapy—formerly known as low-level laser therapy—to alleviate these symptoms, the biological mechanisms behind its success have remained partially obscured.
New insights are emerging from the analysis of salivary biomarkers, offering a clearer picture of how light therapy modulates the body’s inflammatory response. Research indicates that both intraoral and extraoral application of PBM can significantly reduce oxidative stress and inflammatory cytokines in saliva, though the optimal delivery method continues to be a subject of rigorous clinical investigation.
Understanding the Oxidative Storm
To understand why light therapy works, one must first understand the biological chaos caused by radiation. According to Dr. Stephen Sonis, a leading researcher in the field, radiation-induced oral mucositis occurs when biological challenges exceed the body’s physiologic protective mechanisms. This process triggers a cascade of events, prominently featuring oxidative stress.
Oxidative stress arises when there is an imbalance between reactive oxygen species (ROS) and the body’s antioxidant defenses. In the context of radiotherapy, this imbalance damages DNA and cellular structures within the oral mucosa. Studies have shown that markers of this stress, such as malondialdehyde, rise significantly in the saliva of head and neck cancer patients during treatment, while antioxidant levels like glutathione often plummet.
Photobiomodulation appears to intervene in this cycle. By delivering specific wavelengths of light to the tissue, PBM stimulates mitochondrial function, specifically the enzyme cytochrome c oxidase. This stimulation enhances cellular energy production (ATP) and helps restore the redox balance, effectively calming the oxidative storm that drives tissue breakdown.
Intraoral vs. Extraoral: The Delivery Debate
A critical question for oncologists and dental specialists is how best to deliver this therapy. Traditionally, PBM has been applied intraorally, meaning the laser probe is placed directly inside the mouth against the mucosal tissue. However, this can be difficult for patients with severe pain or trismus (lockjaw). Extraoral application, where the laser is applied to the skin overlying the affected area, offers a non-contact alternative.
Comparative studies suggest both methods hold merit. Research involving animal models has demonstrated that both intraoral and extraoral laser therapy can reduce the severity of chemotherapy-induced oral mucositis. In clinical settings, randomized trials have compared these approaches in patients undergoing hematopoietic cell transplantation and head and neck radiotherapy.
While some data suggests intraoral application may provide more direct energy delivery to the superficial mucosa, extraoral techniques have shown efficacy in reducing inflammation without causing patient discomfort. A multicenter, randomized clinical trial published in Supportive Care in Cancer highlighted the viability of comparing these modalities, noting that patient tolerance is a significant factor in adherence to prophylactic protocols.
Saliva as a Diagnostic Window
One of the most promising developments in this field is the use of saliva not just as a lubricant, but as a diagnostic fluid. Saliva contains a rich profile of inflammatory mediators and oxidative markers that mirror the status of the oral mucosa.
Research published in Lasers in Surgery and Medicine has evaluated the effect of PBM on nitrite and inflammatory activity in radiotherapy-induced oral mucositis. The findings suggest that effective laser therapy correlates with a measurable decrease in pro-inflammatory cytokines within the saliva. Similarly, other studies have tracked levels of myeloperoxidase, an enzyme associated with neutrophil activity and inflammation, finding that successful management of mucositis often parallels a reduction in these salivary markers.
This biochemical feedback loop is crucial. It moves the assessment of PBM efficacy beyond subjective pain scales (like the WHO grading system) to objective molecular data. When patients report less pain, their saliva often confirms a reduction in the biological drivers of that pain.
Clinical Guidelines and Future Directions
The accumulating evidence has influenced clinical practice guidelines. The Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) has updated its recommendations to include PBM for the prevention of oral mucositis in specific patient populations, particularly those receiving hematopoietic stem cell transplantation and head and neck radiation.
However, standardization remains a hurdle. Variables such as wavelength, power density and treatment frequency vary across studies. Future research is expected to focus on optimizing these parameters to maximize the modulation of oxidative stress while minimizing treatment time.
For now, the integration of PBM into supportive cancer care represents a significant step forward. By targeting the root biological causes of mucositis—oxidative stress and inflammation—rather than just treating the symptoms, light therapy offers a pathway to preserve quality of life during some of the most challenging moments of cancer treatment.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Patients should consult with their oncology team before starting any new supportive care therapies, including photobiomodulation.
As research continues, the next major checkpoint for this field involves the publication of long-term outcomes from ongoing multicenter trials comparing laser parameters. These results will support refine the global standards for preventing radiation toxicity.
Share your thoughts on supportive cancer care innovations in the comments below.
